- My Alerts
- Go Ad-Free
-
My Account
In App
BSE Live
May 21, 16:00Prev. Close
6.29
Open Price
6.29
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
May 21, 15:57Prev. Close
6.40
Open Price
6.40
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
6.40 (235962)
| Cash Flow of Dr. Datson Labs (in Rs. Cr.) | Mar 14 | Mar 13 | Mar 12 | |
| 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 1.09 | 2.65 | 0.00 | |
| Net CashFlow From Operating Activities | 134.48 | 37.93 | 0.00 | |
| Net Cash Used In Investing Activities | -225.56 | -34.40 | 0.00 | |
| Net Cash Used From Financing Activities | -119.98 | 204.53 | 0.00 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -211.06 | 208.06 | 0.00 | |
| Cash And Cash Equivalents Begin of Year | 212.55 | 4.48 | 0.00 | |
| Cash And Cash Equivalents End Of Year | 1.48 | 212.55 | 0.00 |
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth
